Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared by the board on November 3, 2025. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 24, 2025. This provides a concrete cash return timetable for VTRS shareholders.
Locus Biosciences announced a research collaboration with Viatris (NASDAQ: VTRS) on October 28, 2025 to develop precision engineered bacteriophage therapeutics for serious ophthalmic bacterial infections.
The collaboration will apply Locus’s platform—predictive AI, high-throughput robotics, and synthetic biology—to create bacteriophage cocktails aimed at selectively eliminating eye-pathogenic bacteria while sparing beneficial species. The program targets infections complicated by rising antibiotic resistance and seeks to advance phage-based alternatives or complements to traditional antibiotics.
Viatris (Nasdaq: VTRS) completed the acquisition of Aculys Pharma, acquiring exclusive Japan development and commercialization rights to pitolisant and exclusive Japan and select Asia‑Pacific rights to Spydia Nasal Spray.
Viatris said pitolisant showed strong Phase 3 results in Japanese patients and is on track for an MHLW marketing application for narcolepsy and OSAS-related daytime sleepiness by end of 2025. Spydia received approval in Japan in June 2025 for status epilepticus. Transaction consideration includes an upfront payment, contingent regulatory/commercial milestone payments, and royalties on net sales.
Viatris (Nasdaq: VTRS) will participate in two investor events in November 2025. The company will appear in a fireside chat at the UBS Global Healthcare Conference on November 11, 2025 at 8:45 a.m. ET, and in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 11:30 a.m. GMT / 6:30 a.m. ET. Investors and the public can listen live and access archived sessions at investor.viatris.com for a limited time after each event.
Viatris (Nasdaq: VTRS) was named to Forbes' World's Best Employers 2025, marking the company's fifth consecutive year on the list. The ranking, compiled by Forbes and Statista, surveyed more than 300,000 participants across 50 countries and included 900 companies.
Viatris highlighted workplace priorities such as wellbeing, inclusivity, learning and development, and noted prior recognitions including TIME's World's Most Sustainable Companies 2024 and Forbes' World's Top Companies for Women 2024. More information is available on Viatris' careers site and its 2024 Sustainability Report.
Viatris Inc. (NASDAQ: VTRS) has scheduled its third quarter 2025 financial results announcement for Thursday, November 6, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly performance.
Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay will be available on the company's website following the presentation.
Viatris (NASDAQ: VTRS) has appointed Andrew Enrietti as Chief Administrative and Transformation Officer in a newly created position. Enrietti, who previously served as Chief People Officer, will oversee multiple key functions including Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate.
With over 20 years of career experience, including 10 years at Viatris and its legacy companies, Enrietti brings expertise in financial services, M&A, talent strategy, and organizational effectiveness. The appointment aims to centralize leadership of the company's digital, cultural, and structural transformation initiatives to accelerate strategic evolution.
Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.
The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.
Viatris (NASDAQ:VTRS) reported strong Q2 2025 results, with total revenues of $3.58 billion, down 6% year-over-year but exceeding expectations. The company's adjusted EPS reached $0.62, while adjusted EBITDA was $1.1 billion. Despite challenges, Viatris demonstrated resilience across its global business segments.
Key highlights include positive results from five Phase 3 clinical trials and significant capital returns to shareholders totaling $630 million year-to-date, including $350 million in share buybacks. The company reiterated its 2025 financial guidance, expecting to perform in the top half of the range for total revenues and adjusted EPS.
Regional performance showed strength in Greater China with 9% growth, while other markets faced some headwinds. The company continues to advance its late-stage pipeline and maintains its commitment to strategic growth initiatives for 2026 and beyond.
Viatris (NASDAQ:VTRS) has announced its latest quarterly dividend declaration. The company's Board of Directors has declared a dividend of $0.12 per share on August 4, 2025. The dividend will be paid on September 15, 2025, to shareholders who hold Viatris stock as of the close of business on August 22, 2025.